Back to today’s briefing

Story perspectives

New Study Reassesses Hormone Therapy for Breast Cancer Survivors

10/1/2025

42 5

Summary

Story summary

University College London study on hormone replacement therapy for breast cancer survivors questions prior guidelines that contraindicated HRT.
Expert Consensus Statement recommends individualized risk assessment and shared decision-making on HRT.
Vaginal estrogen has minimal systemic absorption and does not significantly raise relapse risk.
Systemic HRT carries a 6% relapse risk for moderate-risk patients, with 80% recurrence-free.

1 of 1

Story summary

University College London study on hormone replacement therapy for breast cancer survivors questions prior guidelines that contraindicated HRT.
Expert Consensus Statement recommends individualized risk assessment and shared decision-making on HRT.
Vaginal estrogen has minimal systemic absorption and does not significantly raise relapse risk.
Systemic HRT carries a 6% relapse risk for moderate-risk patients, with 80% recurrence-free.